Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (Currently amended) A method of protecting an immune-compromised human from at least one of *Staphylococcal* and *Enterococcal* bacterial infection, comprising administering a vaccine comprising a glycoconjugate of a polysaccharide or glycopeptide bacterial surface antigen and an immunocarrier to an immune-compromised human, wherein said vaccine comprises~~:~~

~~(a)~~ glycoconjugates of both Type 5 and Type 8 polysaccharide antigens of *S. aureus*~~;~~

~~(b) a glycoconjugate of a negatively-charged *Staphylococcal* polysaccharide antigen that comprises β-linked hexosamine as a major carbohydrate component and contains no O-acetyl groups,~~

~~(c) a glycoconjugate of *Staphylococcal* glycopeptide antigen that comprises amino acids and a N-acetylated hexosamine in an α-configuration, that contains no O-acetyl groups, and that contains no hexose,~~

~~(d) a glycoconjugate of an acidic *Staphylococcal* polysaccharide antigen that is obtained from an isolate of *S. epidermidis* that agglutinates antisera to ATCC 55254,~~

~~(e) a glycoconjugate of an *E. faecalis* antigen that comprises 2-acetamido-2-deoxy-glucose and rhamnose in a 1:2 molar ratio,~~

~~(f) a glycoconjugate of an *E. faecalis* antigen that comprises a trisaccharide repeat which comprises a 6-deoxy sugar,~~

~~(g) a glycoconjugate of an *E. faecium* antigen that comprises 2-acetamido-2-deoxy-galactose and galactose in a 2:1 molar ration,~~

~~(h) a glycoconjugate of an *E. faecium* antigen that reacts with antibodies to ATCC 202016, or~~

~~(i) a glycoconjugate of an *E. faecium* antigen that reacts with antibodies to ATCC 202017~~.

Claims 2-13 (canceled)

14. (Original) A method according to claim 1, wherein said immune-compromised human is selected from the group consisting of end stage renal disease (ESRD) patients~~,~~; cancer patients on immunosuppressive therapy, ~~AIDS patients~~, diabetic patients, ~~neonates~~, the elderly in extended care facilities, ~~patients with autoimmune disease on immunosuppressive therapy~~, transplant patients, patients with invasive surgical procedures, ~~burn patients~~ and other patients in acute care settings.

15. (Original) A method according to claim 1, wherein said immune-compromised human suffers from end stage renal disease.

16. (Original) A method according to claim 1, wherein said immune-compromised human is a neonate.

17. (Original) A method according to claim 1, wherein said immunocarrier is diphtheria toxoid, tetanus toxoid, recombinantly produced, genetically detoxified variants thereof or a recombinantly-produced, non-toxic-mutant of *Pseudomonas aeruginosa* exotoxin A or *Staphylococcal* exotoxin or toxoid.

18. (Original) A method according to claim 1, wherein said vaccine additionally comprises an adjuvant or immuostimulant.

19. (Original) A method according to claim 1, wherein said vaccine additionally comprises a β-glucan or granulocyte colony stimulating factor.